Ovoca Gold (OVB) AI Stock Analysis

• Market Cap: £937.98K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 81,563,805
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 5.37
• Price to Book (P/B): 194.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -352.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 1.00p ▼(-13.04% Downside)

The score is driven primarily by weak financial performance typical of a high-risk, pre-revenue biotech—ongoing losses, negative 2024 free cash flow, and significant equity erosion—partly offset by having no debt. Technicals add further caution due to very weak momentum (RSI ~10) and price below the 200-day average, while valuation provides limited support because the negative P/E is not informative and no dividend yield is available.

Ovoca Gold Business Overview & Revenue Model

Company Description

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

How the Company Makes Money

Ovoca Gold Financial Statement Overview

Summary

Pre-revenue with continued losses and uneven cash flow (free cash flow negative in 2024), alongside a sharply shrinking equity base. The key offset is zero debt, which reduces near-term balance sheet risk but does not remove dilution/financing risk if cash burn persists.

Income Statement

The company has reported no revenue across the provided annual periods, consistent with an early-stage biotech profile. Losses remain substantial (net income was -746k in 2024 vs. -4.7m in 2023 and -5.6m in 2022), showing improvement in the latest year but still no clear path to self-sustaining profitability. Operating results are volatile, and margins are effectively non-informative given zero revenue.

Balance Sheet

The balance sheet shows no debt, which materially reduces financial risk and provides flexibility. However, the equity base has fallen sharply over time (from 18.6m in 2020 to 2.1m in 2024) and returns on equity are persistently negative, reflecting ongoing losses and capital erosion. Assets have also declined meaningfully, which limits the cushion available to absorb continued cash burn.

Cash Flow

Cash generation is inconsistent: operating cash flow was positive in 2023 (1.1m) but reverted to a large outflow in 2024 (-1.1m), with free cash flow also negative in 2024 (-1.1m). Earlier years were generally cash-consuming, indicating reliance on external funding or asset sales to sustain operations. While the cash burn improved versus the very large outflows seen in 2021–2022, the return to negative free cash flow in 2024 is a key risk signal.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-1.09M	51.00K	-549.00K	-3.44M	-5.78M	-2.13M
Net Income	-1.24M	-746.00K	-4.70M	-5.61M	-5.47M	-2.34M
Balance Sheet
Total Assets	3.10M	2.65M	3.47M	9.40M	14.77M	19.04M
Cash, Cash Equivalents and Short-Term Investments	2.92M	2.51M	3.34M	3.70M	6.59M	10.75M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	862.00K	594.00K	967.00K	1.77M	1.34M	486.00K
Stockholders Equity	2.24M	2.06M	2.50M	7.63M	13.43M	18.55M
Cash Flow
Free Cash Flow	-1.39K	-1.14M	1.07M	-5.21M	-4.55M	-2.54M
Operating Cash Flow	-1.39K	-1.14M	1.11M	-5.16M	-4.38M	-2.11M
Investing Cash Flow	0.00	0.00	-49.00K	1.51M	-67.00K	7.58M
Financing Cash Flow	-3.00	0.00	-879.00K	900.00K	0.00	-4.09M

Ovoca Gold Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRTX	44 Neutral	£5.30M	-2.20	-88.05%	―	―	―
ROQ	44 Neutral	£1.88M	-1.80	-18.71%	―	―	―
OVB	43 Neutral	£937.98K	-4.11	3.93%	―	―	―

Ovoca Gold Corporate Events

Ovoca Bio to Rebrand as Talisman Metals After Reverse Takeover of Moroccan Copper Explorer

Ovoca Bio has agreed a share-based deal to acquire up to 100% of Tadeen International Limited, a UK company whose Moroccan subsidiary holds copper-focused mineral exploration licences, marking a reverse takeover that will convert Ovoca from an AIM cash shell into an operating mining exploration business. Alongside the transaction, Ovoca plans a 3‑for‑1 share consolidation, a rebrand to Talisman Metals plc with a new AIM ticker, and has raised £1.16m before expenses to fund initial work on its core Moroccan permits and provide working capital, with trading in its shares remaining suspended pending shareholder approval at an extraordinary general meeting and readmission to AIM.

Ovoca Bio Sets Date and Details for 2025 Annual General Meeting in Dublin

Ovoca Bio has published and begun posting to shareholders the notice of its 2025 Annual General Meeting, which sets out the resolutions to be put to investors and is also available on the company’s website. The AGM is scheduled to take place at The Mespil Hotel in Dublin on 27 January 2026 at 10:30 a.m., with further details on shareholder participation provided in the meeting documentation, underscoring the company’s adherence to governance and regulatory requirements on AIM.

Ovoca Bio Appoints New Broker Amid Acquisition Plans

Ovoca Bio PLC, a company in the biotechnology sector, has announced a change in its brokerage arrangement. The company has appointed CMC Markets UK Plc, trading as CMC CapX, as its new broker, while Beaumont Cornish Limited will continue as its Nominated Adviser. This change is in anticipation of the completion of Ovoca’s acquisition of Tadeen International Limited, which was initially announced earlier in the year. This strategic move could potentially enhance Ovoca’s market operations and strengthen its industry positioning.